{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:26:59Z","timestamp":1790771219232,"version":"4.1.0"},"reference-count":83,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowarfare agents including Francisella tularensis, Yersinia pestis and Coxiella burnetii (which cause pneumonic tularemia, plague and Q fever, respectively). Delivery of an antibiotic formulation via the inhalation route has the potential to provide high concentrations at the site of infection with reduced systemic exposure to limit side effects. A liposomal formulation may improve tolerability, increase compliance by reducing the dosing frequency, and enhance penetration of biofilms and treatment of intracellular infections. Two liposomal ciprofloxacin formulations (Lipoquin\u00ae and Pulmaquin\u00ae) that are in development by Aradigm Corporation are described here.<\/jats:p>","DOI":"10.3390\/pharmaceutics8010006","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T11:07:19Z","timestamp":1456830439000},"page":"6","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["Development of Liposomal Ciprofloxacin to Treat Lung Infections"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-4721","authenticated-orcid":false,"given":"David","family":"Cipolla","sequence":"first","affiliation":[{"name":"Aradigm Corp., Hayward, CA 94545, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Aradigm Corp., Hayward, CA 94545, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Gonda","sequence":"additional","affiliation":[{"name":"Aradigm Corp., Hayward, CA 94545, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/ppa.13.47","article-title":"Inhaled Antibiotics to Treat Lung Infection","volume":"2","author":"Cipolla","year":"2013","journal-title":"Pharm. Patent Analyst."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Inhaled antimicrobial therapy - barriers to effective treatment","volume":"85","author":"Weers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/46.5.669","article-title":"Application of fluoroquinolone pharmacodynamics","volume":"46","author":"Wright","year":"2000","journal-title":"J Antimicrob. Chemo."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-Induced Nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1128\/AAC.38.3.547","article-title":"Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin","volume":"38","author":"Fink","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/archinte.1989.00390100083020","article-title":"Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication","volume":"149","author":"Peloquin","year":"1989","journal-title":"Arch. Intern Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1128\/AAC.42.11.2848","article-title":"MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model","volume":"42","author":"Firsov","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","unstructured":"Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., and Young, P.M. Inhaled liposomal ciprofloxacin: Once a day management of respiratory infections. Proceedings of Respiratory Drug Delivery 2010."},{"key":"ref_10","first-page":"354","article-title":"Safety, Tolerability, Pharmacokinetics and Antimicrobial Activity of Inhaled Liposomal Ciprofloxacin Formulations in Humans","volume":"45","author":"Bruinenberg","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/j.1875-9114.1991.tb03596.x","article-title":"Respiratory Tract Penetration of Quinolone Antimicrobials: A Case in Study","volume":"11","author":"Rotrovato","year":"1991","journal-title":"Pharmacotherapy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1128\/JCM.42.5.1915-1922.2004","article-title":"Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis","volume":"42","author":"Moskowitz","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2217\/fmb.12.88","article-title":"Pseudomonas infection in chronic obstructive pulmonary disease","volume":"7","author":"Parameswaran","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_15","first-page":"1602","article-title":"A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis","volume":"2","author":"Finch","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1586\/14787210.2014.952282","article-title":"Antimicrobial treatment of non-cystic fibrosis bronchiectasis","volume":"12","author":"Grimwood","year":"2014","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","article-title":"Prevalence of nontuberculosis mycobacterial lung disease in US Medicare beneficiaries","volume":"185","author":"Adjemian","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Olivier, K.N., Gupta, R., Daley, C.L., Winthrop, K.L., Ruoss, S., Addrizzo-Harris, D.J., Flume, P., Dorgan, D., Salathe, M.A., and Brown-Elliott, B.A. (2014, January 20). A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease. Presented at ATS Conference, San Diego, CA, USA. Available online: http:\/\/www.insmed.com\/publications-presentations\/.","DOI":"10.1016\/S1569-1993(15)30009-6"},{"key":"ref_24","unstructured":"Ruoss, S., Eagle, G., McGinnis, J.P., Micioni, L., Daley, C.L., Winthrop, K.L., Addrizzo-Harris, D.J., Flume, P., Dorgan, D., and Salathe, M. (2015, January 20). Analysis of Functional Exercise Capacity (via the Six-Minute Walk Test [6MWT]) and Negative Sputum Culture for Nontuberculous Mycobacteria (NTM) in Patients With NTM Lung Infection Refractory to Guideline-Based Therapy Treated With Liposomal Amikacin for Inhalation (LAI). Presented at ATS Conference, Denver, CO, USA. Available online: http:\/\/www.insmed.com\/publications-presentations\/."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rose, S.J., Neville, M.E., Gupta, R., and Bermudez, L.E. (2014). Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108703"},{"key":"ref_26","unstructured":"Blanchard, J., Danelishvili, L., Gonda, I., and Bermudez, L. (2014, January 20). Liposomal Ciprofloxacin Preparation is Active against Mycobacterium Avium Subsp Hominissuis and Mycobacterium Abscessus in Macrophages and in Biofilm. Presented at ATS Conference, San Diego, CA, USA. Available online: http:\/\/investor.aradigm.com\/releasedetail.cfm?ReleaseID=840192."},{"key":"ref_27","unstructured":"Blanchard, J., Danelishvili, L., Gonda, I., and Bermudez, L. Treatment of lung infection caused by Mycobacterium abscessus in Beige mice with pulmonary delivery of liposomally encapsulated ciprofloxacin is associated with significant reduction of bacterial load. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Available online: http:\/\/investor.aradigm.com\/releasedetail.cfm?ReleaseID=930955."},{"key":"ref_28","first-page":"A6293","article-title":"Treatment of Mycobacterium avium subsp hominissuis (MAH) lung infection with liposome-encapsulated ciprofloxacin resulted in significant decrease in bacterial load in the lung","volume":"191","author":"Bermudez","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J. Antimicrob. Chemo."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/tde.13.71","article-title":"Liposomal Formulations for Inhalation","volume":"4","author":"Cipolla","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.addr.2014.05.001","article-title":"Lipid-based carriers for pulmonary products: Preclinical development and case studies in Humans","volume":"75","author":"Cipolla","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_32","unstructured":"Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., and Young, P.M. (2011). Proceedings of Respiratory Drug Delivery Europe 2011, Davis Healthcare International Publishing."},{"key":"ref_33","unstructured":"Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., and Farr, S.J. (2006). Proceedings of Respiratory Drug Delivery 2006, Davis Healthcare International Publishing."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1128\/AAC.42.1.45","article-title":"Antibacterial Efficacy Against an in Vivo Salmonella Typhimurium Infection Model and Pharmacokinetics of a Liposomal Ciprofloxacin Formulation","volume":"42","author":"Webb","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/AAC.31.7.1075","article-title":"Altered pharmacologic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits","volume":"31","author":"Barriere","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","unstructured":"Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., and Farr, S.J. (2006). Proceedings of Respiratory Drug Delivery 2006, Davis Healthcare International Publishing."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0168-3659(03)00358-4","article-title":"Liposome Delivery of Ciprofloxacin against Intracellular Francisella tularensis Infection","volume":"92","author":"Wong","year":"2003","journal-title":"J. Control. Release"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s11095-012-0827-0","article-title":"Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia","volume":"29","author":"Ong","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpb.2013.06.024","article-title":"In Vitro and ex Vivo Methods Predict the Enhanced Lung Residence Time of Liposomal Ciprofloxacin Formulations for Nebulisation","volume":"86","author":"Ong","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jamp.2008.0686","article-title":"Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size","volume":"21","author":"Li","year":"2008","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"ref_41","unstructured":"Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., and Young, P.M. (2010). Proceedings of Respiratory Drug Delivery 2010, Davis Healthcare International Publishing."},{"key":"ref_42","unstructured":"Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., and Young, P.M. (2013). Proceedings of Respiratory Drug Delivery Europe 2013, Davis Healthcare International Publishing."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jps.23795","article-title":"Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation","volume":"103","author":"Cipolla","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(98)00055-6","article-title":"Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin","volume":"167","author":"Finlay","year":"1998","journal-title":"Int. J. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0009-3084(93)90053-6","article-title":"Chemical stability of liposomes: Implications for their physical stability","volume":"64","author":"Grit","year":"1993","journal-title":"Chem. Phys. Lipids."},{"key":"ref_46","first-page":"A-27","article-title":"Dual Release Ciprofloxacin for Inhalation (DRCFI) Improves Time to First Exacerbation in Bronchiectasis","volume":"24","author":"Cipolla","year":"2011","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0927-7757(00)00516-1","article-title":"Cryo transmission electron microscopy of liposomes and related structures","volume":"174","author":"Almgren","year":"2000","journal-title":"Colloids Surf. A"},{"key":"ref_48","unstructured":"FDA Draft Guidance for Industry. Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation October 2015, Available online: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm070570.pdf."},{"key":"ref_49","unstructured":"ICH Quality Guidelines. Available online: http:\/\/www.ich.org\/products\/guidelines\/quality\/article\/quality-guidelines.html."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1128\/AAC.02555-13","article-title":"Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4","volume":"58","author":"Hamblin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","first-page":"A-16","article-title":"Efficacy of inhaled liposome-encapsulated ciprofloxacin against Yersinia pestis","volume":"26","author":"Hamblin","year":"2013","journal-title":"J. Aer. Med. Pulm. Drug Deliv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1128\/AAC.03443-14","article-title":"Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever","volume":"58","author":"Norville","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jmri.21440","article-title":"Monitoring infection and inflammation in murine models of cystic fibrosis with magnetic resonance imaging","volume":"28","author":"Sheth","year":"2008","journal-title":"J. Magn. Reson. Imaging."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1001\/jama.285.21.2763","article-title":"Working Group on Civilian Biodefense. Tularemia as a biological weapon: Medical and public health management","volume":"285","author":"Dennis","year":"2001","journal-title":"JAMA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1086\/322601","article-title":"Tularemia epidemic in northwestern Spain: Clinical description and therapeutic response","volume":"33","author":"Herreros","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1086\/313946","article-title":"Treatment of tularemia with ciprofloxacin","volume":"31","author":"Chocarro","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14787210.6.2.231","article-title":"Tularemia: Current diagnosis and treatment options","volume":"6","author":"Hepburn","year":"2008","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijantimicag.2006.02.006","article-title":"Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin","volume":"27","author":"Steward","year":"2006","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1128\/AAC.41.6.1288","article-title":"Aerosol delivery of liposome-encapsulated ciprofloxacin: Aerosol characterization and efficacy against Francisella tularensis infection in mice","volume":"41","author":"Conley","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/infdis\/168.3.793","article-title":"Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of BALB\/c mice against Francisella tularensis","volume":"168","author":"Cherwanogrodzky","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fcimb.2014.00079","article-title":"The Potential of Liposome-Encapsulated Ciprofloxacin as a Tularemia Therapy","volume":"4","author":"Hamblin","year":"2014","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0013-9351(76)90107-9","article-title":"Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation","volume":"11","author":"Brain","year":"1976","journal-title":"Environ. Res."},{"key":"ref_63","unstructured":"FDA Draft Guidance for Industry. Animal models - essential elements to address efficacy under the Animal Rule, Available online: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm399217.pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/CMR.12.4.518","article-title":"Fever","volume":"12","author":"Maurin","year":"1999","journal-title":"Clin Microbiol Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1128\/AAC.49.7.2673-2676.2005","article-title":"Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis","volume":"49","author":"Rolain","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1086\/321889","article-title":"Risks factors and prevention of Q fever endocarditis","volume":"33","author":"Fenollar","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_67","first-page":"1","article-title":"Diagnosis and management of Q fever--United States, 2013: Recommendations from CDC and the Q Fever Working Group","volume":"62(RR-03)","author":"Anderson","year":"2013","journal-title":"MMWR Recomm. Rep."},{"key":"ref_68","unstructured":"CDC Q fever, Available online: http:\/\/www.cdc.gov\/qfever\/index.html."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archinte.159.2.167","article-title":"Treatment of Q fever endocarditis: Comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine","volume":"159","author":"Raoult","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/infdis\/166.5.1097","article-title":"Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm","volume":"166","author":"Maurin","year":"1992","journal-title":"J Infect Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1128\/JB.01856-12","article-title":"Genome sequence of Coxiella burnetii 109, a doxycycline-resistant clinical isolate","volume":"194","author":"Rouli","year":"2012","journal-title":"J. Bacteriol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1128\/AAC.42.10.2747","article-title":"In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin","volume":"42","author":"Gikas","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/jamp.2007.0652","article-title":"Aerosolized antibiotics for non-cystic fibrosis bronchiectasis","volume":"21","author":"Rubin","year":"2008","journal-title":"J. Aer. Med. Pulm. Drug Deliv."},{"key":"ref_74","unstructured":"Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., and Young, P.M. (2014). Proceedings of Respiratory Drug Delivery 2014, Davis Healthcare International Publishing."},{"key":"ref_75","first-page":"354","article-title":"Safety, Tolerability, Pharmacokinetics and Antimicrobial Activity of Inhaled Liposomal Ciprofloxacin Formulations in Humans. North American Cystic Fibrosis Conference","volume":"45","author":"Bruinenberg","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Bruinenberg, P., Blanchard, J., Cipolla, D., and Serisier, D. (2010). Safety, Tolerability and Pharmacokinetics of Novel Liposomal Ciprofloxacin Formulations for Inhalation in Healthy Volunteers and in Non-Cystic Bronchiectasis Patients. ATS International Conference.","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A3192"},{"key":"ref_77","unstructured":"Aradigm press release on 13 October 2015. Available online: http:\/\/investor.aradigm.com\/releasedetail.cfm?ReleaseID=936283."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4155\/tde.10.54","article-title":"Personalized Medicine: Development of Inhalation Systems Tailored to the Individual","volume":"1","author":"Cipolla","year":"2010","journal-title":"Ther. Deliv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/jps.23969","article-title":"Modifying the Release Properties of Liposomes toward Personalized Medicine","volume":"103","author":"Cipolla","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1039\/C5RA25898G","article-title":"Formation of Drug Nanocrystals under Nanoconfinement Afforded by Liposomes","volume":"6","author":"Cipolla","year":"2016","journal-title":"RSC Adv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1208\/s12249-014-0155-2","article-title":"Aerosol performance and long term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties","volume":"15","author":"Cipolla","year":"2014","journal-title":"AAPS PharmSciTech."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/jamp.2015.1241","article-title":"Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals","volume":"28","author":"Cipolla","year":"2015","journal-title":"J. Aer. Med. Pulm. Drug Deliv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/08982109209018634","article-title":"Liposome Aerosols","volume":"2","author":"Schreier","year":"1992","journal-title":"J. Liposome Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/8\/1\/6\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:19:57Z","timestamp":1760210397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/8\/1\/6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["pharmaceutics8010006"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics8010006","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}